Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HLVX 
Hillevax Inc (HLVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: HLVX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.08% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 105.76M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 2 | Beta 0.77 | 52 Weeks Range 1.34 - 2.17 | Updated Date 09/12/2025 |
52 Weeks Range 1.34 - 2.17 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.44 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.48% | Return on Equity (TTM) -40.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -31242620 | Price to Sales(TTM) - |
Enterprise Value -31242620 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.07 | Shares Outstanding 50125500 | Shares Floating 27408113 |
Shares Outstanding 50125500 | Shares Floating 27408113 | ||
Percent Insiders 17.09 | Percent Institutions 70.44 |
Upturn AI SWOT
Hillevax Inc
Company Overview
History and Background
Hillevax, Inc., is a biopharmaceutical company founded in 2021 dedicated to developing and commercializing novel vaccines against norovirus, a leading cause of acute gastroenteritis. They focus on addressing significant unmet needs in public health.
Core Business Areas
- Norovirus Vaccine Development: Hillevax's primary focus is the development of HIL-214, their lead vaccine candidate for norovirus. This involves research, clinical trials, and regulatory approvals.
Leadership and Structure
The leadership team includes experienced professionals in vaccine development, clinical research, and business development. Organizational structure is typical of a biotech company focusing on R&D and clinical trials.
Top Products and Market Share
Key Offerings
- HIL-214 (Norovirus Vaccine Candidate): HIL-214 is Hillevax's leading norovirus vaccine candidate currently undergoing clinical trials. Market share is currently 0% as the vaccine is pre-commercialization. Competitors for norovirus vaccines include Takeda (TAK) and VBI Vaccines (VBIV). Takeda's vaccine is farther along in regulatory approval.
Market Dynamics
Industry Overview
The vaccine market is large and growing, driven by increasing awareness of infectious diseases and government initiatives to promote vaccination. The norovirus vaccine market is currently untapped but represents a significant opportunity.
Positioning
Hillevax is positioned as a key player in developing a norovirus vaccine, aiming to capture a significant share of the potential market. Their competitive advantage lies in their innovative vaccine technology and focus on norovirus.
Total Addressable Market (TAM)
The estimated global TAM for norovirus vaccines is several billion USD annually, assuming successful development and broad adoption. Hillevax aims to capture a substantial portion of this TAM.
Upturn SWOT Analysis
Strengths
- Novel vaccine technology
- Experienced management team
- Focus on a significant unmet need
- Strong intellectual property position
Weaknesses
- Dependence on a single product candidate
- Early-stage company with limited commercial experience
- High risk associated with clinical trials
- Need for significant capital to fund development
Opportunities
- Successful clinical trials and regulatory approval
- Partnerships with pharmaceutical companies
- Expansion to new markets
- Potential for future vaccine development programs
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing norovirus vaccines
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- TAK
- VBIV
Competitive Landscape
Hillevax is in a competitive race to develop a norovirus vaccine. Success depends on safety, efficacy, and speed to market.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to being a relatively new company.
Future Projections: Future growth is dependent on the successful development and commercialization of HIL-214. Analyst projections will vary based on clinical trial progress and market potential.
Recent Initiatives: Recent initiatives include advancing HIL-214 through clinical trials and seeking partnerships for manufacturing and commercialization.
Summary
Hillevax is an early-stage biopharmaceutical company with a promising norovirus vaccine candidate. Its success hinges on positive clinical trial outcomes and regulatory approval. The company faces significant risks associated with drug development but also has substantial growth potential in a large, underserved market. Hillevax needs to carefully manage its cash burn and secure partnerships to navigate the regulatory landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hillevax Inc. website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor. The biotechnology industry is inherently risky, and clinical trial outcomes are uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hillevax Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2022-04-29 | Co-Founder, President, CEO & Chairman of the Board Dr. Robert M. Hershberg M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.hillevax.com |
Full time employees 14 | Website https://www.hillevax.com | ||
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.